Actively Recruiting
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
Led by M.D. Anderson Cancer Center · Updated on 2026-04-15
11
Participants Needed
1
Research Sites
511 weeks
Total Duration
On this page
Sponsors
M
M.D. Anderson Cancer Center
Lead Sponsor
C
Cancer Prevention Research Institute of Texas
Collaborating Sponsor
AI-Summary
What this Trial Is About
To find the highest tolerable dose of stereotactic hypofractionated radioablation (HYDRA) radiation that can be given to patients with laryngeal cancer. The safety of this radiation will also be studied.
CONDITIONS
Official Title
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Older than 18 years of age with confirmed squamous cell carcinoma of the larynx
- Disease stage T1N1 or T2-4aN0-1 as defined by AJCC criteria
- ECOG performance status between 0 and 2
- Functionally and technically fit for partial laryngectomy, confirmed by physician evaluation
- Women of child-bearing potential and men agree to use adequate contraception during study and for 90 days after
- Women of child-bearing potential have not undergone hysterectomy or bilateral oophorectomy and are not naturally postmenopausal for at least 12 months
- Ability to understand English and willing to sign informed consent
You will not qualify if you...
- Previous surgery removing the primary laryngeal cancer
- Previous induction chemotherapy for this cancer
- Diverting tracheostomy directly through tumor or placed for true airway insufficiency (except preemptive tracheostomy for airway compromise)
- Prior cancer diagnosis except treated localized epithelial skin or cervical cancer
- Prior radiation therapy to head and neck
- Women of child-bearing potential and men not practicing effective contraception during the study
- Unable or unwilling to give written informed consent
- Severe active co-morbidities including recent unstable angina, heart failure, recent heart attack, acute infection needing IV antibiotics, recent respiratory illness, liver insufficiency, AIDS, or recent potent immunosuppressive treatment
- Pregnant or nursing women
- Evidence of metastatic disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
J
Jack Phan, MD, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here